{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["PDAC gene profile", "cannabidiol", "chemo-resistance", "cytotoxicity", "migration", "oxygen-ozone", "pancreatic cancer"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "32992648", "DateRevised": {"Year": "2020", "Month": "11", "Day": "03"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2020", "Month": "09", "Day": "27"}], "ELocationID": ["2774", "10.3390/cancers12102774"], "Journal": {"ISSN": "2072-6694", "JournalIssue": {"Volume": "12", "Issue": "10", "PubDate": {"Year": "2020", "Month": "Sep", "Day": "27"}}, "Title": "Cancers", "ISOAbbreviation": "Cancers (Basel)"}, "ArticleTitle": "Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines.", "Abstract": {"AbstractText": ["Pancreatic cancer (PC) is related to lifestyle risks, chronic inflammation, and germline mutations in <i>BRCA1/2</i>, <i>ATM</i>, <i>MLH1</i>, <i>TP53</i>, or <i>CDKN2A</i>. Surgical resection and adjuvant chemotherapy are the main therapeutic strategies but are less effective in patients with high-grade tumors. Oxygen-ozone (O<sub>2</sub>/O<sub>3</sub>) therapy is an emerging alternative tool for the treatment of several clinical disorders. O<sub>2</sub>/O<sub>3</sub> therapy has been found to ameliorate mechanisms promoting chronic pain and inflammation, including hypoxia, inflammatory mediators, and infection. The advantages of using cannabinoids have been evaluated in vitro and in vivo models of several human cancers. Regarding PDAC, activation of cannabinoid receptors was found to induce pancreatic cancer cell apoptosis without affecting the normal pancreas cells. In a murine model of PDAC, a combination of cannabidiol (CBD) and gemcitabine increased survival length by nearly three times. Herein, we evaluate the anticancer effect of CBD and O<sub>2</sub>/O<sub>3</sub>, alone or in combination, on two human PDAC cell lines, PANC-1 and MiaPaCa-2, examining expression profiles of 92 pancreatic adenocarcinoma associated genes, cytotoxicity, migration properties, and cell death. Finally, we assess the combination effects with gemcitabine and paclitaxel. Summarizing, for the first time the antitumoral effect of combined therapy with CBD and oxygen-ozone therapy in PDAC is evidenced."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "\"Maria Guarino\" Foundation-AMOR No Profit Association, 80078 Pozzuoli, Italy."}], "LastName": "Luongo", "ForeName": "Margherita", "Initials": "M"}, {"Identifier": ["0000-0001-5518-5303"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, University of Camerino, 62032 Camerino (MC), Italy."}], "LastName": "Marinelli", "ForeName": "Oliviero", "Initials": "O"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, University of Camerino, 62032 Camerino (MC), Italy."}], "LastName": "Zeppa", "ForeName": "Laura", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, University of Camerino, 62032 Camerino (MC), Italy."}], "LastName": "Aguzzi", "ForeName": "Cristina", "Initials": "C"}, {"Identifier": ["0000-0002-4614-5649"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, University of Camerino, 62032 Camerino (MC), Italy."}], "LastName": "Morelli", "ForeName": "Maria Beatrice", "Initials": "MB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Bioscience and Veterinary Medicine, University of Camerino, 62032 Camerino (MC), Italy."}], "LastName": "Amantini", "ForeName": "Consuelo", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "\"Maria Guarino\" Foundation-AMOR No Profit Association, 80078 Pozzuoli, Italy."}], "LastName": "Frassineti", "ForeName": "Andrea", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "\"Maria Guarino\" Foundation-AMOR No Profit Association, 80078 Pozzuoli, Italy."}], "LastName": "di Costanzo", "ForeName": "Marianne", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Radiotherapy, Ecomedica Empoli, 50053 Empoli FI, Italy."}], "LastName": "Fanelli", "ForeName": "Alessandro", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, University of Camerino, 62032 Camerino (MC), Italy."}], "LastName": "Santoni", "ForeName": "Giorgio", "Initials": "G"}, {"Identifier": ["0000-0003-0165-1385"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, University of Camerino, 62032 Camerino (MC), Italy."}, {"Identifier": [], "Affiliation": "Integrative Therapy Discovery Lab, University of Camerino, 62032 Camerino (MC), Italy."}], "LastName": "Nabissi", "ForeName": "Massimo", "Initials": "M"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Cancers (Basel)", "NlmUniqueID": "101526829", "ISSNLinking": "2072-6694"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Amantini C., Morelli M.B., Nabissi M., Piva F., Marinelli O., Maggi F., Bianchi F., Bittoni A., Berardi R., Giampieri R., et al. Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival. Front. Oncol. 2019;9:874. doi: 10.3389/fonc.2019.00874.", "ArticleIdList": ["10.3389/fonc.2019.00874", "PMC6746928", "31552188"]}, {"Citation": "Luchini C., Capelli P., Scarpa A. Pancreatic Ductal Adenocarcinoma and Its Variants. Surg. Pathol. Clin. 2016;9:547\u2013560. doi: 10.1016/j.path.2016.05.003.", "ArticleIdList": ["10.1016/j.path.2016.05.003", "27926359"]}, {"Citation": "Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7\u201330. doi: 10.3322/caac.21442.", "ArticleIdList": ["10.3322/caac.21442", "29313949"]}, {"Citation": "Adamska A., Domenichini A., Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int. J. Mol. Sci. 2017;18:1338. doi: 10.3390/ijms18071338.", "ArticleIdList": ["10.3390/ijms18071338", "PMC5535831", "28640192"]}, {"Citation": "Ansari D., Tingstedt B., Andersson B., Holmquist F., Sturesson C., Williamsson C., Sasor A., Borg D., Bauden M., Andersson R. Pancreatic cancer: Yesterday, today and tomorrow. Future Oncol. 2016;12:1929\u20131946. doi: 10.2217/fon-2016-0010.", "ArticleIdList": ["10.2217/fon-2016-0010", "27246628"]}, {"Citation": "Hu C., Hart S.N., Polley E.C., Gnanaolivu R., Shimelis H., Lee K.Y., Lilyquist J., Na J., Moore R., Antwi S.O., et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018;319:2401\u20132409. doi: 10.1001/jama.2018.6228.", "ArticleIdList": ["10.1001/jama.2018.6228", "PMC6092184", "29922827"]}, {"Citation": "Felsenstein M., Hruban R.H., Wood L.D. New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Adv. Anat. Pathol. 2018;25:131\u2013142. doi: 10.1097/PAP.0000000000000172.", "ArticleIdList": ["10.1097/PAP.0000000000000172", "PMC6365013", "28914620"]}, {"Citation": "Wolfgang C.L., Herman J.M., Laheru D.A., Klein A.P., Erdek M.A., Fishman E.K., Hruban R.H. Recent progress in pancreatic cancer. CA Cancer J. Clin. 2013;63:318\u2013348. doi: 10.3322/caac.21190.", "ArticleIdList": ["10.3322/caac.21190", "PMC3769458", "23856911"]}, {"Citation": "Gillen S., Schuster T., Meyer Zum B\u00fcschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267. doi: 10.1371/journal.pmed.1000267.", "ArticleIdList": ["10.1371/journal.pmed.1000267", "PMC2857873", "20422030"]}, {"Citation": "Werner J., Combs S.E., Springfeld C., Hartwig W., Hackert T., B\u00fcchler M.W. Advanced-stage pancreatic cancer: Therapy options. Nat. Rev. Clin. Oncol. 2013;10:323\u2013333. doi: 10.1038/nrclinonc.2013.66.", "ArticleIdList": ["10.1038/nrclinonc.2013.66", "23629472"]}, {"Citation": "Murphy J.E., Wo J.Y., Ryan D.P., Clark J.W., Jiang W., Yeap B.Y., Drapek L.C., Ly L., Baglini C.V., Blaszkowsky L.S. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5:1020\u20131027. doi: 10.1001/jamaoncol.2019.0892.", "ArticleIdList": ["10.1001/jamaoncol.2019.0892", "PMC6547247", "31145418"]}, {"Citation": "Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012;366:2455\u20132465. doi: 10.1056/NEJMoa1200694.", "ArticleIdList": ["10.1056/NEJMoa1200694", "PMC3563263", "22658128"]}, {"Citation": "Royal R.E., Levy C., Turner K., Mathur A., Hughes M., Kammula U.S., Sherry R.M., Topalian S.L., Yang J.C., Lowy I. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010;33:828\u2013833. doi: 10.1097/CJI.0b013e3181eec14c.", "ArticleIdList": ["10.1097/CJI.0b013e3181eec14c", "PMC7322622", "20842054"]}, {"Citation": "Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer. 2011;11:393\u2013410. doi: 10.1038/nrc3064.", "ArticleIdList": ["10.1038/nrc3064", "21606941"]}, {"Citation": "Baran N., Konopleva M. Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy. Clin. Cancer Res. 2017;23:2382\u20132390. doi: 10.1158/1078-0432.CCR-16-0895.", "ArticleIdList": ["10.1158/1078-0432.CCR-16-0895", "PMC5433896", "28137923"]}, {"Citation": "Karakashev S.V., Reginato M.J. Progress toward overcoming hypoxia-induced resistance to solid tumor therapy. Cancer Manag. Res. 2015;7:253\u2013264. doi: 10.2147/CMAR.S58285.", "ArticleIdList": ["10.2147/CMAR.S58285", "PMC4542411", "26316817"]}, {"Citation": "Manoochehri Khoshinani H., Afshar S., Najafi R. Hypoxia: A Double-Edged Sword in Cancer Therapy. Cancer Investig. 2016;34:536\u2013545. doi: 10.1080/07357907.2016.1245317.", "ArticleIdList": ["10.1080/07357907.2016.1245317", "27824512"]}, {"Citation": "Luongo M., Brigida A.L., Mascolo L., Gaudino G. Possible Therapeutic Effects of Ozone Mixture on Hypoxia in Tumor Development. Anticancer Res. 2017;37:425\u2013435. doi: 10.21873/anticanres.11334.", "ArticleIdList": ["10.21873/anticanres.11334", "28179287"]}, {"Citation": "Bocci V.A. Scientific and medical aspects of ozone therapy. State of the art. Arch. Med. Res. 2006;37:425\u2013435. doi: 10.1016/j.arcmed.2005.08.006.", "ArticleIdList": ["10.1016/j.arcmed.2005.08.006", "16624639"]}, {"Citation": "Fuccio C., Luongo C., Capodanno P., Giordano C., Scafuro M.A., Siniscalco D., Lettieri B., Rossi F., Maione S., Berrino L. A single subcutaneous injection of ozone prevents allodynia and decreases the over-expression of pro-inflammatory caspases in the orbito-frontal cortex of neuropathic mice. Eur. J. Pharmacol. 2009;603(Suppl. S1\u2013S3):42\u201349. doi: 10.1016/j.ejphar.2008.11.060.", "ArticleIdList": ["10.1016/j.ejphar.2008.11.060", "19100257"]}, {"Citation": "Di Filippo C., Trotta M.C., Maisto R., Siniscalco D., Luongo M., Mascolo L., Alfano R., Accardo M., Rossi C., Ferraraccio F., et al. Daily Oxygen/O3 Treatment Reduces Muscular Fatigue and Improves Cardiac Performance in Rats Subjected to Prolonged High Intensity Physical Exercise. Oxid. Med. Cell Longev. 2015;2015:190640. doi: 10.1155/2015/190640.", "ArticleIdList": ["10.1155/2015/190640", "PMC4523667", "26265981"]}, {"Citation": "Rowen R.J., Robins H. Ozone Therapy for Complex Regional Pain Syndrome: Review and Case Report. Curr. Pain Headache Rep. 2019;23:41. doi: 10.1007/s11916-019-0776-y.", "ArticleIdList": ["10.1007/s11916-019-0776-y", "PMC6502773", "31062104"]}, {"Citation": "Z\u00e4nker K.S., Kroczek R. In vitro synergistic activity of 5-fluorouracil with low-dose ozone against a chemoresistant tumor cell line and fresh human tumor cells. Chemotherapy. 1990;36:147\u2013154. doi: 10.1159/000238761.", "ArticleIdList": ["10.1159/000238761", "2311442"]}, {"Citation": "Cannizzaro A., Verga Falzacappa C.V., Martinelli M., Misiti S., Brunetti E., Bucci B. O(2/3) exposure inhibits cell progression affecting cyclin B1/cdk1 activity in SK-N-SH while induces apoptosis in SK-N-DZ neuroblastoma cells. J. Cell Physiol. 2007;213:115\u2013125. doi: 10.1002/jcp.21097.", "ArticleIdList": ["10.1002/jcp.21097", "17477375"]}, {"Citation": "Afrin F., Chi M., Eamens A.L., Duchatel R.J., Douglas A.M., Schneider J., Gedye C., Woldu A.S., Dun M.D. Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer. Cancers. 2020;12:1033. doi: 10.3390/cancers12041033.", "ArticleIdList": ["10.3390/cancers12041033", "PMC7226605", "32340151"]}, {"Citation": "Nabissi M., Morelli M.B., Offidani M., Amantini C., Gentili S., Soriani A., Cardinali C., Leoni P., Santoni G. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016;7:77543\u201377557. doi: 10.18632/oncotarget.12721.", "ArticleIdList": ["10.18632/oncotarget.12721", "PMC5363603", "27769052"]}, {"Citation": "Velasco G., S\u00e1nchez C., Guzm\u00e1n M. Anticancer mechanisms of cannabinoids. Curr. Oncol. 2016;23:S23\u2013S32. doi: 10.3747/co.23.3080.", "ArticleIdList": ["10.3747/co.23.3080", "PMC4791144", "27022311"]}, {"Citation": "Marinelli O., Morelli M.B., Annibali D., Aguzzi C., Zeppa L., Tuyaerts S., Amantini C., Amant F., Ferretti B., Maggi F., et al. The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer. Int. J. Mol. Sci. 2020;21:5409. doi: 10.3390/ijms21155409.", "ArticleIdList": ["10.3390/ijms21155409", "PMC7432565", "32751388"]}, {"Citation": "Jeong S., Yun H.K., Jeong Y.A., Jo M.J., Kang S.H., Kim J.L., Kim D.Y., Park S.H., Kim B.R., Na Y.J., et al. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Lett. 2019;447:12\u201323. doi: 10.1016/j.canlet.2019.01.011.", "ArticleIdList": ["10.1016/j.canlet.2019.01.011", "30660647"]}, {"Citation": "Morelli M.B., Offidani M., Alesiani F., Discepoli G., Liberati S., Olivieri A., Santoni M., Santoni G., Leoni P., Nabissi M. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. Int. J. Cancer. 2014;134:2534\u20132546. doi: 10.1002/ijc.28591.", "ArticleIdList": ["10.1002/ijc.28591", "24293211"]}, {"Citation": "Michalski C.W., Oti F.E., Erkan M., Sauliunaite D., Bergmann F., Pacher P., Batkai S., M\u00fcller M.W., Giese N.A., Friess H., et al. Cannabinoids in pancreatic cancer: Correlation with survival and pain. Int. J. Cancer. 2008;122:742\u2013750. doi: 10.1002/ijc.23114.", "ArticleIdList": ["10.1002/ijc.23114", "PMC2225529", "17943729"]}, {"Citation": "Fogli S., Nieri P., Chicca A., Adinolfi B., Mariotti V., Iacopetti P., Breschi M.C., Pellegrini S. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett. 2006;580:1733\u20131739. doi: 10.1016/j.febslet.2006.02.024.", "ArticleIdList": ["10.1016/j.febslet.2006.02.024", "16500647"]}, {"Citation": "Ferro R., Adamska A., Lattanzio R., Mavrommati I., Edling C.E., Arifin S.A., Fyffe C.A., Sala G., Sacchetto L., Chiorino G., et al. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene. 2018;37:6368\u20136382. doi: 10.1038/s41388-018-0390-1.", "ArticleIdList": ["10.1038/s41388-018-0390-1", "30061636"]}, {"Citation": "Donadelli M., Dando I., Zaniboni T., Costanzo C., Dalla Pozza E., Scupoli M.T., Scarpa A., Zappavigna S., Marra M., Abbruzzese A., et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011;2:e152. doi: 10.1038/cddis.2011.36.", "ArticleIdList": ["10.1038/cddis.2011.36", "PMC3122066", "21525939"]}, {"Citation": "Orth M., Metzger P., Gerum S., Mayerle J., Schneider G., Belka C., Schnurr M., Lauber K. Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat. Oncol. 2019;14:141. doi: 10.1186/s13014-019-1345-6.", "ArticleIdList": ["10.1186/s13014-019-1345-6", "PMC6688256", "31395068"]}, {"Citation": "Manji G.A., Olive K.P., Saenger Y.M., Oberstein P. Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clin. Cancer Res. 2017;23:1670\u20131678. doi: 10.1158/1078-0432.CCR-16-2319.", "ArticleIdList": ["10.1158/1078-0432.CCR-16-2319", "28373365"]}, {"Citation": "Conroy T., Desseigne F., Ychou M., Bouch\u00e9 O., Guimbaud R., B\u00e9couarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardi\u00e8re C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364:1817\u20131825. doi: 10.1056/NEJMoa1011923.", "ArticleIdList": ["10.1056/NEJMoa1011923", "21561347"]}, {"Citation": "Muller C., Morales P., Reggio P.H. Cannabinoid Ligands Targeting TRP Channels. Front. Mol. Neurosci. 2019;11:487. doi: 10.3389/fnmol.2018.00487.", "ArticleIdList": ["10.3389/fnmol.2018.00487", "PMC6340993", "30697147"]}, {"Citation": "De Petrocellis L., Nabissi M., Santoni G., Ligresti A. Actions and Regulation of Ionotropic Cannabinoid Receptors. Adv. Pharmacol. 2017;80:249\u2013289. doi: 10.1016/bs.apha.2017.04.001.", "ArticleIdList": ["10.1016/bs.apha.2017.04.001", "28826537"]}, {"Citation": "Carracedo A., Gironella M., Lorente M., Garcia S., Guzm\u00e1n M., Velasco G., Iovanna J.L. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006;66:6748\u20136755. doi: 10.1158/0008-5472.CAN-06-0169.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-0169", "16818650"]}, {"Citation": "Guo X., Ling X., Du F., Wang Q., Huang W., Wang Z., Ding X., Bai M., Wu Z. Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe. Transl. Oncol. 2018;11:1065\u20131073. doi: 10.1016/j.tranon.2018.06.009.", "ArticleIdList": ["10.1016/j.tranon.2018.06.009", "PMC6043890", "30005208"]}, {"Citation": "Roberto D., Klotz L.H., Venkateswaran V. Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner. Prostate. 2019;79:151\u2013159. doi: 10.1002/pros.23720.", "ArticleIdList": ["10.1002/pros.23720", "30242861"]}, {"Citation": "Kuroda K., Azuma K., Mori T., Kawamoto K., Murahata Y., Tsuka T., Osaki T., Ito N., Imagawa T., Itoh F., et al. The Safety and Anti-Tumor Effects of Ozonated Water in Vivo. Int. J. Mol. Sci. 2015;16:25108\u201325120. doi: 10.3390/ijms161025108.", "ArticleIdList": ["10.3390/ijms161025108", "PMC4632793", "26506343"]}, {"Citation": "Nabissi M., Morelli M.B., Santoni M., Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis. 2013;34:48\u201357. doi: 10.1093/carcin/bgs328.", "ArticleIdList": ["10.1093/carcin/bgs328", "23079154"]}, {"Citation": "Du J., Nelson E.S., Simons A.L., Olney K.E., Moser J.C., Schrock H.E., Wagner B.A., Buettner G.R., Smith B.J., Teoh M.L., et al. Regulation of pancreatic cancer growth by superoxide. Mol. Carcinog. 2013;52:555\u2013567. doi: 10.1002/mc.21891.", "ArticleIdList": ["10.1002/mc.21891", "PMC3375391", "22392697"]}, {"Citation": "Poma A., Colafarina S., Aruffo E., Zarivi O., Bonfigli A., Di Bucchianico S., Di Carlo P. Effects of ozone exposure on human epithelial adenocarcinoma and normal fibroblasts cells. PLoS ONE. 2017;12:e0184519. doi: 10.1371/journal.pone.0184519.", "ArticleIdList": ["10.1371/journal.pone.0184519", "PMC5590931", "28886142"]}, {"Citation": "Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801\u20131806. doi: 10.1126/science.1164368.", "ArticleIdList": ["10.1126/science.1164368", "PMC2848990", "18772397"]}, {"Citation": "Raphael B.J., Hruban R.H., Aguirre A.J., Moffitt R.A., Yeh J.J., Stewart C., Robertson A.G., Cherniack A.D., Gupta M. Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185\u2013203.e13. doi: 10.1016/j.ccell.2017.07.007.", "ArticleIdList": ["10.1016/j.ccell.2017.07.007", "PMC5964983", "28810144"]}, {"Citation": "Roberts N.J., Norris A.L., Petersen G.M., Bondym M.L., Brand R., Gallinger S., Kurtz R.C., Olson S.H., Rustgi A.K., Schwartz A.G., et al. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov. 2016;6:166\u2013175. doi: 10.1158/2159-8290.CD-15-0402.", "ArticleIdList": ["10.1158/2159-8290.CD-15-0402", "PMC4744563", "26658419"]}, {"Citation": "Buscail L., Bournet B., Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2020;17:153\u2013168. doi: 10.1038/s41575-019-0245-4.", "ArticleIdList": ["10.1038/s41575-019-0245-4", "32005945"]}, {"Citation": "Collisson E.A., Trejo C.L., Silva J.M., Gu S., Korkola J.E., Heiser L.M., Charles R.P., Rabinovich B.A., Hann B., Dankort D., et al. A central role for RAF\u2192MEK\u2192ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012;2:685\u2013693. doi: 10.1158/2159-8290.CD-11-0347.", "ArticleIdList": ["10.1158/2159-8290.CD-11-0347", "PMC3425446", "22628411"]}, {"Citation": "Eser S., Reiff N., Messer M., Seidler B., Gottschalk K., Dobler M., Hieber M., Arbeiter A., Klein S., Kong B., et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell. 2013;23:406\u2013420. doi: 10.1016/j.ccr.2013.01.023.", "ArticleIdList": ["10.1016/j.ccr.2013.01.023", "23453624"]}, {"Citation": "Altomare D.A., Tanno S., de Rienzo A., Klein-Szanto A.J., Tanno S., Skele K.L., Hoffman J.P., Testa J.R. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J. Cell Biochem. 2002;87:470\u2013476. doi: 10.1002/jcb.10287.", "ArticleIdList": ["10.1002/jcb.10287", "14735903"]}, {"Citation": "Ying H., Dey P., Yao W., Kimmelman A.C., Draetta G.F., Maitra A., DePinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355\u2013385. doi: 10.1101/gad.275776.115.", "ArticleIdList": ["10.1101/gad.275776.115", "PMC4762423", "26883357"]}, {"Citation": "Contis J., Lykoudis P.M., Goula K., Karandrea D., Kondi-Pafiti A. Survivin expression as an independent predictor of overall survival in pancreatic adenocarcinoma. J. Cancer Res. Ther. 2018;14(Suppl. S14):S719\u2013S723. doi: 10.4103/0973-1482.187346.", "ArticleIdList": ["10.4103/0973-1482.187346", "30249893"]}, {"Citation": "Papademetrio D.L., Lompard\u00eda S.L., Simunovich T., Costantino S., Mihalez C.Y., Cavaliere V., \u00c1lvarez \u00c9. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy. Target. Oncol. 2016;11:183\u2013195. doi: 10.1007/s11523-015-0388-3.", "ArticleIdList": ["10.1007/s11523-015-0388-3", "26373299"]}, {"Citation": "Schmitt A., Feldmann G., Zander T., Reinhardt H.C. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. Oncol. Res. Treat. 2018;41:619\u2013625. doi: 10.1159/000493401.", "ArticleIdList": ["10.1159/000493401", "30286473"]}, {"Citation": "Cao L., Li W., Kim S., Brodie S.G., Deng C.X. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev. 2003;17:201\u2013213. doi: 10.1101/gad.1050003.", "ArticleIdList": ["10.1101/gad.1050003", "PMC195980", "12533509"]}, {"Citation": "Carlos A.R., Escandell J.M., Kotsantis P., Suwaki N., Bouwman P., Badie S., Folio C., Benitez J., Gomez-Lopez G., Pisano D.G., et al. ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets. Nat. Commun. 2013;4:2697. doi: 10.1038/ncomms3697.", "ArticleIdList": ["10.1038/ncomms3697", "24162189"]}, {"Citation": "Heijink A.M., Talens F., Jae L.T., van Gijn S.E., Fehrmann R.S.N., Brummelkamp T.R., van Vugt M.A.T.M. BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. Nat. Commun. 2019;10:100. doi: 10.1038/s41467-018-07927-y.", "ArticleIdList": ["10.1038/s41467-018-07927-y", "PMC6327059", "30626869"]}, {"Citation": "Yako Y.Y., Kruger D., Smith M., Brand M. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. PLoS ONE. 2016;11:e0154016. doi: 10.1371/journal.pone.0154016.", "ArticleIdList": ["10.1371/journal.pone.0154016", "PMC4865360", "27170998"]}, {"Citation": "Ling J., Kang Y., Zhao R., Xia Q., Lee D.F., Chang Z., Li J., Peng B., Fleming J.B., Wang H., et al. KrasG12D-induced IKK2/\u03b2/NF-\u03baB activation by IL-1\u03b1 and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:105\u2013120. doi: 10.1016/j.ccr.2011.12.006.", "ArticleIdList": ["10.1016/j.ccr.2011.12.006", "PMC3360958", "22264792"]}, {"Citation": "Hausmann S., Kong B., Michalski C., Erkan M., Friess H. The role of inflammation in pancreatic cancer. Adv. Exp. Med. Biol. 2014;816:129\u2013151. doi: 10.1007/978-3-0348-0837-8_6.", "ArticleIdList": ["10.1007/978-3-0348-0837-8_6", "24818722"]}, {"Citation": "Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 2007;67:3853\u20133861. doi: 10.1158/0008-5472.CAN-06-4257.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-4257", "17440100"]}, {"Citation": "Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45. doi: 10.1093/nar/29.9.e45.", "ArticleIdList": ["10.1093/nar/29.9.e45", "PMC55695", "11328886"]}, {"Citation": "Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006;58:621\u2013681. doi: 10.1124/pr.58.3.10.", "ArticleIdList": ["10.1124/pr.58.3.10", "16968952"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "6", "Day": "10"}, {"Year": "2020", "Month": "9", "Day": "10"}, {"Year": "2020", "Month": "9", "Day": "24"}, {"Year": "2020", "Month": "9", "Day": "30", "Hour": "1", "Minute": "1"}, {"Year": "2020", "Month": "10", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "10", "Day": "1", "Hour": "6", "Minute": "1"}, {"Year": "2020", "Month": "9", "Day": "27"}], "PublicationStatus": "epublish", "ArticleIdList": ["32992648", "PMC7600087", "10.3390/cancers12102774", "cancers12102774"]}}], "PubmedBookArticle": []}